APA Zitierstil

Raedler, L. A. (2016). Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma. Am Health Drug Benefits.

Chicago Zitierstil

Raedler, Lisa A. "Pomalyst (Pomalidomide) Received a New Indication for Patients With Relapsed And/or Refractory Multiple Myeloma." Am Health Drug Benefits 2016.

MLA Zitierstil

Raedler, Lisa A. "Pomalyst (Pomalidomide) Received a New Indication for Patients With Relapsed And/or Refractory Multiple Myeloma." Am Health Drug Benefits 2016.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.